FT: Dassault Systèmes might be adding to its life sciences offering

The Financial Times reported yesterday (and I haven’t been able to verify) that Dassault Systèmes is in talks to buy drug trial software maker ArisGlobal from Nordic Capital for about $2 billion. The FT article mostly discusses what Nordic Capital would get from the deal (cash to return to shareholders and/or to spend on other acquisitions), but we should also consider what this might mean for Dassault Systèmes (DS).

DS acquired Medidata for $5.8 billion in 2019 and BIOVIA (fka Accelrys) for $750 million in 2012. Accelrys brought materials science applications — meaning chemical modeling and simulation, scaling processes from workbench to production, electronic lab notebook capabilities, and more—that DS combined with capabilities it was developing in-house for the life sciences industry. Medidata (and the work DS subsequently did on integration) connects discovery, research, and clinical trials to create what DS calls “end-to-end digital continuity” for the life sciences industry.

Why might ArisGlobal be interesting to DS? ArisGlobal makes drug safety/efficacy and regulatory-compliance solutions that would extend Medidata’s clinical trial platform, giving DS more to sell to those customers. But it’s more than that: According to ArisGlobal, it has specialized AI capabilities that it delivers via its LifeSphere NavaX, which uses AI to automate tasks such as processing adverse drug events, case triage, translating doctor-speak and patient-speak to better classify outcomes and identify side effects, and then speed up creation of the necessary regulatory filings.

ArisGlobal says it currently serves “more than 220 global life sciences companies, CROs [I think that stands for Contract Research Organization — Ed.], and government health authorities, including leading biopharmaceutical firms and regulatory bodies such as FDA, Health Canada, and NMPA” and has nearly 1,300 employees. According to Nordic Capital, ArisGlobal’s 2025 revenue was EUR 150 million.

We can see why ArisGlobal might be interesting to DS, given its potential to add to DS’s AI capabilities and offer more to its life sciences customers. And DS should indeed continue its push to diversify beyond auto and aero. And it’s also true that Nordic Capital seems to want an off-ramp from ArisGlobal, so the price could be attractive. Still, $2 billion seems expensive … if it were to go through, this would be DS’ second largest deal, after Medidata.

The Financial Times piece ran yesterday, 16 July 2026. As of early 17 July 2027, none of the companies involved have made a public statement—so this may very well be a false alarm. DS announces Q2 results on 23 July, and may make a statement then.